| 17 Octobre 2014
(Livingston, NJ, USA, 15.10.2014 ) The SyncroPatch 384/768PE offers the highest throughput in automated patch clamping history. The SyncroPatch 384/768PE focuses on providing both high quality recordings together with broad experimental versatility, two important hallmarks that clearly convinced scientific researchers at the Northwestern University Feinberg School of Medicine, Chicago, IL.The SyncroPatch 384/768PE is an advanced robotic screening platform that investigates the effects of chemical compounds and toxins on ion channel function. The instrument supports high quality recordings from up to 768 cells simultaneously, allowing high throughput screening of ligand- and voltage-gated ion channels expressed in cell lines, stem cells or patient-derived cells.
The SyncroPatch 384PE/768 PE combines high versatility and data quality by supporting fast solution exchange, brief compound exposure, internal perfusion and minimal cell usage. The minimal cell usage application improves cost efficiency while allowing screening capabilities with cells of limited availability such as primary cells or otherwise rare and expensive stem cells or patient-derived cells. Entering the market in 2013, the SyncroPatch 384/768PE was rapidly adopted by renowned pharmaceutical companies, contract research organizations and biotech companies, following a strong trend which includes academic research institutions. Academic core facilities have blossomed all across America over the past years, providing researchers with the ability to run high throughput and high content screens for drug or target discovery that not too long ago was strictly exclusive to Big Pharma and biotech companies. By blending the strength and standardization of Big Pharma with the intelligence and acumen of basic research, core facilities can now contend with more ambitious projects that call for larger resources.
Dr. Al George, Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA says:
“We are extraordinarily excited about installing the first SyncroPatch 384PE in an academic setting in North America. The enormous throughput, intuitive software and robust liquid handling capabilities along with superior seal quality, stability and high success rates convinced us to purchase the instrument. The SyncroPatch 384PE will enable us to perform detailed high throughput analysis of genetic variants in human ion channels at a previously unobtainable scale, and will form the cornerstone of a new HTS facility we are building. We also look forward to upgrading to 768 wells in the near future.”
Rodolfo Haedo, Vice President Nanion Technologies Inc. continues:
“The acquisition of the SyncroPatch 384/768PE by the prestigious facility at Northwestern University Feinberg School of Medicine confirms the trend we’re experiencing, that the SyncroPatch 384/768PE is receiving a great deal of attention by the finest scientific research laboratories in the world. We are extremely excited to work with Dr. George and the groups involved at Northwestern University as they work at the interface of ion channel pharmacology and channelopathy research. We will finally have the opportunity to see the implementation of many different applications, ranging from hard-core biophysical characterization of patient-specific ion channel mutations, as well as target directed drug screening for personalized medicine, which in turn will continue to push the boundaries of what to expect from a patch clamp-based HTS system.”